Lactobacillus Reuteri – NCIMB 30242

Update: 2018 Summary on L Reuteri.

This species is used by multiple manufacturers. The 2012 FDA letter (154 pages) is quoted below.

  • “L. reuteri NCIMB 30242 may reasonably occur among U.S. consumers seeking foods for the nutritional maintenance of healthy cholesterol levels. L. reuteri NCIMB 30242 will not be added to infant formula, and foods to which L. reuteri NCIMB 30242 will be added will not be marketed for use by infants.
  • “Currently, the strain is manufactured at Chr Hansen (Denmark) using current Good Manufacturing Practices (cGMP). “
  • 1.32 to 2.83 108 CFU/g
  • “Based on the current long-history of use of L. reuteri in food (i.e., probiotic products, and sourdough bread fermentation), and the fact that the species is natural commensal in many animals including humans, the absence of case-reports of infectivity strongly support that the species can be declared non-pathogenic. “
  • “with respect to measures of colonic microflora, other than Bacteroidetes which were increased two- to three-fold in the L. reuteri groups relative to the saline controls, no significant differences between groups were noted.”
  • Like the prior L. Reuteri DSM 17938 (BioGaia), this is sensitive to (easily killed by) most antibiotics:
    “genes associated with resistance to fluoroquinolones. These antibiotic resistance elements were demonstrated to be common to other lactobacilli”

Screen Shot 2015-11-28 at 10.40.21 PM

  • “As reported by Branton et al. (2011) L. reuteri NCIMB 30242 is known to ferment lactose to the above lactic acid mixture in a ratio of 45:55%”i.e. D-Lactic to L-Lactic ratio
  • “Lactobacillus reuteri NCIMB 30242 did not display inhibitory activity towards the indicator strains, suggesting that this strain of L. reuteri lacks bacteriocin-like antimicrobial activity. “
  • “L. reuteri NCIMB 30242 does not produce measurable quantities of reuterin under these test methods. ” — L. reuteri ATCC 23272  does produce it!
  • “The results show a significant decrease in Aspergillus, from baseline, when comparing treatment and placebo groups. All other bacterial (Eubacteria, BacteroidesIPrevotella, LactobacillusIStreptococcuslEnterococcus, Bifidobacterium, Faecalibacteria, Desulfovibrio, Enterobacteria, Clostridium leptum, Clostridium coccoides, Saccharomyces, Candida ) and fungal measurements showed no significant changes between treatment and placebo groups from baseline.”

Bottom Line

The absence of antibiotic production commonly associated with L. Reuteri as well as being sensitive to almost all antibiotics actually makes this strain a poor choice for dealing with dysfunctional microbiome.